Cyclacel Pharmaceuticals Secures $2.1 Million from Warrant Exercise
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP) is making strides in the biopharmaceutical sector with its recent successful closure of an exercise of existing warrants. This transaction brought in gross proceeds of approximately $2.1 million, a significant boost for the company focused on developing innovative cancer treatments.
Details of the Warrant Exercise
The company announced that it successfully finalized this transaction involving the exercise of nearly 4.97 million shares of its common stock. Initially issued with an exercise price of $1.36 per share, these warrants were exercised at a substantially reduced price of $0.415 per share. The shares that were issued upon this exercise have been registered under an effective registration statement on Form S-1.
H.C. Wainwright & Co. served as the exclusive placement agent for this offering, showcasing the partnership’s role in assisting Cyclacel along this financial journey.
New Warrants Issued
In addition to the exercised warrants, Cyclacel issued fresh Series C and Series D warrants. Both series of warrants allow the purchase of up to 9.93 million shares of common stock at the same reduced price of $0.415 per share. These new warrants are set to become exercisable following the stockholder's approval for their issuance, ensuring that current and prospective investors have clear pathways for future investment.
Use of Proceeds
The net proceeds raised from this offering are intended for working capital and general corporate purposes. This funding will aid Cyclacel Pharmaceuticals in pushing forward its research and development programs, further emphasizing the company's commitment to advancing cancer treatment.
About Cyclacel Pharmaceuticals
Cyclacel is dedicated to developing cutting-edge therapies for cancer, focusing on cell cycle, transcriptional regulation, and mitosis biology. With promising candidates such as fadraciclib, a CDK2/9 inhibitor, and plogosertib, a PLK1 inhibitor, the company's strategic vision revolves around creating a robust portfolio of drug candidates that address various oncology and hematology indications. Their efforts are paving the way for revolutionary treatment options to combat cancer more effectively.
Company Contact
For inquiries, Paul McBarron can be reached directly at (908) 517-7330 or via email at IR@cyclacel.com. Cyclacel Pharmaceuticals is continually looking to enhance its business operations and shareholder value through strategic initiatives and innovations.
Frequently Asked Questions
What is the significance of the recent warrant exercise for Cyclacel?
The warrant exercise generated approximately $2.1 million in funds, critical for financing the company's cancer medicine development efforts.
How will Cyclacel utilize the funds raised?
The company plans to dedicate the net proceeds to working capital and other general corporate purposes.
What are the new warrants issued by Cyclacel?
Cyclacel issued Series C and Series D warrants allowing the purchase of nearly 9.93 million shares each at $0.415 per share contingent upon stockholder approval.
What role did H.C. Wainwright play in this transaction?
H.C. Wainwright & Co. acted as the exclusive placement agent for Cyclacel’s warrant exercise offering.
What is Cyclacel's focus in the pharmaceutical industry?
Cyclacel Pharmaceuticals focuses on developing novel cancer therapies through innovative drug candidates targeting oncology and hematology conditions.
